Business · St. Louis
US judge approves Bayer's $7.25 billion Roundup settlement over blood cancer claims
A Missouri state judge gave final approval on Friday, 20 November, to Bayer's settlement of lawsuits claiming its Roundup weedkiller caused blood cancer. Payments run over up to 21 years and cover current and future non-Hodgkin lymphoma claims.
AI text based on reports by ČT24, Le Monde.fr, newsORF.at and other publishers. Published . How it is made
For membersThe first 30 seconds for everyone. Synthetic voice (AI).
In brief
Judge Timothy Boyer of the St. Louis court approved the settlement in full on Friday, 20 November, and made it final.
Bayer will pay up to $7.25 billion over up to 21 years, covering pending and future non-Hodgkin lymphoma claims.
El Mundo reports that beneficiaries could receive between $10,000 and $165,000 on average, depending on use, age at diagnosis and severity.
In June the US Supreme Court held that Bayer cannot be sued in state courts for failing to warn of cancer, because federal rules do not require such a label.
- 2018Bayer acquires Monsanto, the maker of Roundup.
- February 2026Bayer negotiates the settlement and says it carries no admission of liability or fault.
- June 2026The US Supreme Court rules that Bayer cannot be sued in state courts for failing to warn of cancer.
- 20 NovJudge Timothy Boyer in Missouri approves the $7.25 billion settlement in full.
The ruling
Timothy Boyer, a judge in St. Louis, Missouri, approved on Friday, 20 November, the $7.25 billion settlement that Bayer proposed to end lawsuits alleging its Roundup weedkiller caused cancer. The court approved the agreement in full and made it final. Bayer, the German agrochemical group that acquired Monsanto, the maker of Roundup, in 2018, will pay up to $7.25 billion over up to 21 years. The deal is meant to settle pending lawsuits as well as claims that have not yet been filed.
Who is covered and what they could receive
The agreement covers people who are already ill and people who will be diagnosed with non-Hodgkin lymphoma in the future, according to El Mundo. Beneficiaries could receive on average between $10,000 and $165,000, depending on how they used the product, their age at diagnosis and how severe their illness is. Bayer negotiated the deal in February, when it said the payments carried no admission of liability or fault. Since buying Monsanto, Bayer has paid more than $10 billion to settle a large part of the Roundup claims, ČT24 reports. El Mundo also reports that Bayer had considered withdrawing the product from US agricultural markets because litigation costs kept rising.
Objections and the Supreme Court
Judge Boyer rejected objections that payments to individuals were too low because plaintiffs in earlier settlements received more. He found the deal fair, reasonable and adequate. He warned that delayed payments could force victims, including terminally ill patients, to wait years for their money. Lawyers for cancer patients remain divided: some say the amounts are too low, while others argue the deal is better than receiving nothing, a view strengthened by the Supreme Court's ruling. In June, the US Supreme Court held that Bayer cannot be sued in state courts for failing to warn of cancer risks, because federal rules do not require a cancer warning label and states may not impose additional labeling requirements. Bayer's chief executive Bill Anderson said in a statement that final approval is a decisive milestone in the company's strategy to contain pending and possible future glyphosate lawsuits.
The cancer question
The International Agency for Research on Cancer classifies glyphosate, the main active ingredient in Roundup, as a probable carcinogen for humans. Bayer maintains that scientific studies and approvals by regulators show the product is safe. The company denies that Roundup causes cancer, and specifically denies that it causes non-Hodgkin lymphoma. The court documents and reports cited by the sources do not give a finding on the science itself, only on the settlement.
Background and timeline
Bayer's exposure to Roundup litigation dates back to its 2018 acquisition of Monsanto. The settlement was negotiated in February and approved by the court in November, with the Supreme Court ruling in June falling between those two steps. The approval closes the court process for the settlement, while payments are spread over up to 21 years.
Ask about this text
Sources and context
- ČT24 - Nejdůvěryhodnější zpravodajský web v ČR - Česká televizeUS court approves Bayer's settlement agreement regarding Roundup herbicide lawsuitsSoud v USA schválil dohodu Bayeru o urovnání žalob ohledně herbicidu Roundup · original in Czech
- Le Monde.frUS judge approves $7.25 billion Roundup cancer settlement
- Le Monde.frUnited States: a judge validates a 7.25 billion dollar compensation agreement by Bayer to settle all Roundup-related complaintsEtats-Unis : un juge valide un accord d'indemnisation par Bayer de 7,25 milliards de dollars pour solder l'ensemble des plaintes liées au Roundup · original in French
- newsORF.atGlyphosate dispute: US judge approves Bayer billion-dollar settlementGlyphosat-Streit: US-Richter billigt Bayer-Milliardenvergleich · original in German
- Bill Anderson
- Chief executive of Bayer, who called final approval a decisive milestone in the company's glyphosate litigation strategy.
- Places
- St. Louis, United States, Missouri
Pollar is free and carries no ads in the text. Its members keep it going.
Support Pollar